Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. [electronic resource]
Producer: 20140227Description: 707-14 p. digitalISSN:- 1791-2431
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Carcinoma, Squamous Cell -- drug therapy
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Synergism
- ErbB Receptors -- genetics
- Esophageal Neoplasms -- drug therapy
- Esophageal Squamous Cell Carcinoma
- Fluorouracil -- administration & dosage
- Humans
- Lapatinib
- Male
- Mice
- Mice, Nude
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Phosphorylation -- drug effects
- Quinazolines -- administration & dosage
- Random Allocation
- Receptor, ErbB-2 -- genetics
- Transcriptome -- drug effects
- Xenograft Model Antitumor Assays -- methods
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.